Trials / Completed
CompletedNCT02906683
Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
A Phase IIa Study of TAS-303 in Female Patients With Stress Urinary Incontinence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 337 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.
Detailed description
The main purpose of this study is to assess the efficacy of TAS-303 for 8 weeks in female patients with stress urinary incontinence (SUI) compared with placebo as measured by the percent change in incontinence episode frequency (IEF) from baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-303 | Oral administration for 8 weeks, once daily. |
| DRUG | Placebo | Oral administration for 8 weeks, once daily. |
Timeline
- Start date
- 2016-10-20
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
- First posted
- 2016-09-20
- Last updated
- 2024-09-26
- Results posted
- 2024-09-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02906683. Inclusion in this directory is not an endorsement.